Why Should Insurers Care About Clinical Trials?

episode

JAMA Clinical Reviews not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Essentials: How to Assess & Improve All Aspects of Your Fitness | Dr. Andy Galpin 35 min · 17 Sep 2026 · Huberman Lab

#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung 3h 43m · 17 Sep 2026 · Lex Fridman Podcast

September 16, 2026 PC - Sep 16, 2026 1h 50m · 16 Sep 2026 · Fairfax County Planning Commission

Planning Commision 09/16/2026 - Sep 16, 2026 56 min · 16 Sep 2026 · Prince William County Planning Commission

Western Loudoun Rural Uses and Standards PCZOC Ad Hoc Meeting 2 - Sep 16, 2026 4h 45m · 16 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded01 Jul 2024

Publisherjamaclinicalreviews.libsyn.com ↗

Handlerec:7722563

Show notes

The US is a global leader in introducing new medical products, but the ability to generate evidence to inform clinical practice in postmarket settings must improve. Insurers may have an important role to play. Robert M. Califf, MD, of the US Food and Drug Administration, discusses why and how payers could support evidence generation with JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS. Related Content: Why Evidence Generation Should Matter to Payers and How They Can Help

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in